Trials / Unknown
UnknownNCT04815408
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
A Phase II Study of PD-1 Antibody Plus Neoadjuvant Chemotherapy for Advanced-stage Ovarian Cancer (Z2HOC-01)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-A317 | PD-1 antibody，Tislelizumab (BGB-A317) |
| DRUG | albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 | albumin-bound paclitaxel 260mg/m2 , Carboplatin AUC 5 |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2023-04-01
- Completion
- 2025-04-01
- First posted
- 2021-03-25
- Last updated
- 2021-03-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04815408. Inclusion in this directory is not an endorsement.